Improvement of a decreased anti-oxidative activity by edaravone in amyotrophic lateral sclerosis patients

Journal of the Neurological Sciences - Tập 415 - Trang 116906 - 2020
Yasuyuki Ohta1, Toru Yamashita1, Emi Nomura1, Nozomi Hishikawa1, Ken Ikegami1, Yosuke Osakada1, Namiko Matsumoto1, Yuko Kawahara1, Taijun Yunoki1, Yoshiaki Takahashi1, Motonori Takamiya1, Koh Tadokoro1, Ryo Sasaki1, Yumiko Nakano1, Keiichiro Tsunoda1, Kota Sato1, Yoshio Omote1, Mami Takemoto1, Koji Abe1
1Department of Neurology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, 2-5-1 Shikata-cho, Okayama 700-8558, Japan

Tài liệu tham khảo

Abe, 2014, Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients, Amyotroph Lateral Scler Frontotemporal Degener, 15, 610, 10.3109/21678421.2014.959024

Brown, 2017, Amyotrophic lateral sclerosis, N. Engl. J. Med., 377, 162, 10.1056/NEJMra1603471

Writing, 2017, Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial, Lancet Neurol., 16, 505, 10.1016/S1474-4422(17)30115-1

Cedarbaum, 1997, Performance of the amyotrophic lateral sclerosis functional rating scale (ALSFRS) in multicenter clinical trials, J. Neurol. Sci., 152, S1, 10.1016/S0022-510X(97)00237-2

Yoshino, 2006, Investigation of the therapeutic effects of edaravone, a free radical scavenger, on amyotrophic lateral sclerosis (Phase II study), Amyotroph. Lateral Scler., 7, 241, 10.1080/17482960600881870

Brooks, 2000, El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis, Amyotroph Lateral Scler Other Motor Neuron Disord, 1, 293, 10.1080/146608200300079536

Lacomblez, 1989, A double-blind, placebo-controlled trial of high doses of gangliosides in amyotrophic lateral sclerosis, Neurology, 39, 1635, 10.1212/WNL.39.12.1635

Jenkinson, 1999, Evidence for the validity and reliability of the ALS assessment questionnaire: the ALSAQ-40, Amyotroph Lateral Scler Other Motor Neuron Disord, 1, 33, 10.1080/146608299300080022

Ohta, 2019, Enhanced oxidative stress and the treatment by edaravone in mice model of amyotrophic lateral sclerosis, J. Neurosci. Res., 97, 607, 10.1002/jnr.24368

Tamaki, 2008, Relationship between periodontal condition and plasma reactive oxygen metabolites in patients in the maintenance phase of periodontal treatment, J. Periodontol., 79, 2136, 10.1902/jop.2008.080082

Okada, 2018, Long-term effects of edaravone on survival of patients with amyotrophic lateral sclerosis, eNeurologicalSci, 11, 11, 10.1016/j.ensci.2018.05.001

Miyazaki, 2016, Elevation of serum heat-shock protein levels in amyotrophic lateral sclerosis, Neurol. Sci., 37, 1277, 10.1007/s10072-016-2582-1

Martinez de Toda, 2015, The role of Hsp70 in oxi-inflamm-aging and its use as a potential biomarker of lifespan, Biogerontology, 16, 709, 10.1007/s10522-015-9607-7

Lackie, 2017, The Hsp70/Hsp90 chaperone machinery in neurodegenerative diseases, Front. Neurosci., 11, 254, 10.3389/fnins.2017.00254

Thông tin
Thông tin xuất bản

Journal of the Neurological Sciences

Tập 415

116906

Thông tin tác giả